CD45 Antibody, anti-non-human primate, REAfinity™
Synonyms: LCA, L-CA, T200
RECOMBINANT EXTENDED VALIDATION
Bioz Star94/100 Bioz rating
4 Citations2 Images
Clone:
REA1023 | MB4-6D6
Type of antibody:
Primary antibodies, Recombinant antibodies
Isotype:
recombinant human IgG1
Applications:
FC, MICS, IF, IHC Glossary
External link icon
Quality Assurance Certified ProductSatisfaction
guaranteed
more »
Select a conjugate:
Select a size:
Other sizes

Related products for CD45 Antibody, anti-non-human primate, REAfinity™

Flow cytometry applications
APC
Biotin
FITC
PE
PE-Vio 615
PE-Vio 770
PerCP-Vio 700
Vio Bright R720
VioBlue
VioGreen
Recommended dilution:
1:50
Remark:
Cells should be stained prior to fixation, if formaldehyde is used as a fixative.
Data source:
Miltenyi Biotec
Conjugate:
APC
Used products:
130-117-282, 130-117-191
Description:
Peripheral blood mononuclear cells (PBMCs) from rhesus monkey were stained with CD45 antibodies or with the corresponding REA Control (S) antibodies (left images) and analyzed by flow cytometry using the MACSQuant® Analyzer. Cell debris and dead cells were excluded from the analysis based on scatter signals and propidium iodide fluorescence or 4',6-diamidino-2-phenylindole (DAPI) fluorescence, as in the case of tandem conjugates.

Application imageView details view details

Application imageView details view details
MICS (MACSima Imaging Cyclic Staining) applications
APC
FITC
PE
Fixation:
frozen – PFA
Species tested:
human
Recommended dilution:
1:50
Data source:
Miltenyi Biotec
Compatible applications:
IF, IHC
Conjugate:
APC
Used products:
130-117-282, 130-117-191
Testing grade:
Fixation:
frozen – Acetone
Species tested:
human
Recommended dilution:
1:50
Data source:
Miltenyi Biotec
Compatible applications:
IF, IHC
Conjugate:
APC
Used products:
130-117-282, 130-117-191
Testing grade:
Extended validation for CD45 Antibody, anti-non-human primate, REAfinity™
Specificity
Epitope competition assay

In order to compare the epitope specificity of an antibody, the clone being used is compared with other known clones recognizing the same antigen in a competition assay.

Other clones
Overlap in epitope recognition with REA1023
5B1
low
REA747
low
2D1
low
HI30
low
REAL258
low
MB4-6D6
high

Cells were incubated with an excess of purified unconjugated CD45 (REA1023) antibody followed by staining with fluorochrome-conjugated antibodies from other known clones targeting the same antigen. Fluorescence intensity was then used to assess epitope overlap: a minimal or absent signal indicated high epitope overlap, an intermediate signal suggested partial overlap, and a strong signal reflected low overlap.

Knockout validation

To ensure antibody specificity, the target gene is knocked out in a suitable cell line using the CRISPR/Cas9 system and the knockout is confirmed by sequencing of the target locus. The antibody is considered to bind specifically to the intended epitope if no antibody binding to the knockout cells can be detected. The antibody staining is controlled by fluorescence microscopy and/or flow cytometry.

WT
Extended-Validation detailed information image
KO
Extended-Validation detailed information image

Fluorescence microscopy image of CD45 knockout cells. Wild type (WT, left) and knockout cells (KO, right) were stained with CD45-PE (REA1023, red) and counterstained with DRAQ5 (blue) as DNA stain.

Extended-Validation detailed information image

Overlay histogram showing flow cytometric analysis of human CD45 knockout cells. Wild type (red) and knockout cells (blue) were stained with CD45-PE, clone (REA1023). Flow cytometry was performed with the MACSQuant® Analyzer. Cell debris, dead cells and cell doublets were excluded from the analysis based on scatter signals and propidium iodide fluorescence.

Sensitivity
Performance comparison

Selected fluorochrome conjugated antibodies from Miltenyi Biotec were compared to commercially available hybridoma clones in flow cytometry analysis.

Extended-Validation detailed information image
Extended-Validation detailed information image
Extended-Validation detailed information image

Flow cytometric comparison of different clones for CD45. Rhesus monkey peripheral blood mononuclear cells (PBMCs) were stained with CD45 antibodies and plotted against the side scatter. As a control, CD45 antibody staining was omitted and cells were measured in the same channels. Flow cytometry was performed with the MACSQuant® Analyzer. Cell debris, dead cells, and cell doublets were excluded from the analysis based on scatter signals and 4',6-diamidino-2-phenylindole (DAPI) fluorescence. No FcR Blocking Reagent was used. The recommended titers of respective antibodies from different suppliers were used.

Extended-Validation detailed information image
Extended-Validation detailed information image
Extended-Validation detailed information image
Extended-Validation detailed information image
Extended-Validation detailed information image
Extended-Validation detailed information image

Flow cytometric comparison of different clones for CD45. Human peripheral blood mononuclear cells (PBMCs) were stained with CD45 antibodies and plotted against the side scatter. As a control, CD45 antibody staining was omitted and cells were measured in the same channels. Flow cytometry was performed with the MACSQuant® Analyzer. Cell debris, dead cells, and cell doublets were excluded from the analysis based on scatter signals and propidium iodide fluorescence. No FcR Blocking Reagent was used. The recommended titers of respective antibodies from different suppliers were used.

Extended-Validation detailed information image

Flow cytometric comparison of different clones for CD45 shown as histograms

Fixation data

To provide an indication on how an antibody performs after fixation of cells, in-house data on staining results before and after fixation with 3.7% formaldehyde using Miltenyi Biotec antibodies are provided. Different experimental settings may lead to different results.

No fixation
Extended-Validation detailed information image
Post fixation
Extended-Validation detailed information image

Comparison of staining pattern on non-fixed and fixed cells using CD45 (REA1023). The performance of the antibody after fixation was tested by comparing the staining pattern on fresh (no fixation) versus fixed (post fixation) cells.

No fixation
Extended-Validation detailed information image
Post fixation
Extended-Validation detailed information image

Comparison of staining pattern on non-fixed and fixed cells using CD45 (REA1023). The performance of the antibody after fixation was tested by comparing the staining pattern on fresh (no fixation) versus fixed (post fixation) cells.

Specifications for CD45 Antibody, anti-non-human primate, REAfinity™
Overview

Clone REA1023 recognizes the rhesus monkey (Macaca mulatta) and cynomolgus monkey (Macaca fascicularis) CD45 antigen. It is reported to cross-react with pigtail monkey (Macaca nemestrina) and human. CD45 is a type I membrane glycoprotein also known as leukocyte common antigen (LCA), T200, or receptor-type tyrosine-protein phosphatase C (PTPRC). It is expressed on non-human primate hematopietic cells, such as lymphocytes, monocytes, and granulocytes. It is not found on erythroid cells. CD45 functions as a regulator for cell growth, differentiation, cell cycle, and oncogenic transformation.

Additional information: Clone REA1023 displays negligible binding to Fc receptors.

Alternative names

LCA, L-CA, T200

Detailed product information

Technical specifications

Clone
REA1023
Clonality
monoclonal
Isotype
recombinant human IgG1
Isotype control
REA Control Antibody (S), human IgG1
Host
human cell line
Type of antibody
Primary antibodies, Recombinant antibodies
Species reactivity
human, non-human primate
Cross-reactivity
rhesus monkey (Macaca mulatta), cynomolgus monkey (Macaca fascicularis), human, pigtail monkey (Macaca nemestrina)
Antigen
CD45
Molecular mass of antigen [kDa]
41
Distribution of antigen
granulocytes, lymphocytes, monocytes, leukocytes
Entrez Gene ID
RRID
AB_2727900, AB_2727869, AB_2727901, AB_2727903, AB_2727899, AB_2727862, AB_2727863, AB_2727865, AB_2727905, AB_2727866, AB_2727902, AB_2727904, AB_2727906, AB_2727864, AB_2727867, AB_2921928, AB_2921902, AB_2727868, AB_2727870

Recombinant antibodies at Miltenyi Biotec

As an innovation-powered company with a commitment to quality and excellence, Miltenyi Biotec applies cutting-edge methods to discover and develop newer and better antibodies to satisfy both market demand and regulatory requirements.

The Miltenyi way of generating best-in-class antibodies and antibody conjugates

At Miltenyi Biotec, we opt for recombinant antibodies, which enable sequence verification and optimization for lot-to-lot consistency, making them superior to hybridoma-based antibodies.

Infusing our unique expertise

Recombinants are the result of combining genetic material from different immunized animals, and using display technologies to screen in-house antibody libraries for the best antibodies. Additional analyses on existing hybridoma-based antibodies can also give rise to sequences contributing to novel recombinants.

Maximizing value for your research

By further re-engineering these antibody sequences, we can precisely control their properties to achieve the following benefits:

reduce undesirable binding to Fc gamma receptors,

  • eliminate destabilizing amino acid motifs,
  • increase specific bonding affinity for stronger, more accurate targeting, and
  • optimize fluorochrome conjugation for brighter and clearer signals.

In a final step, by synthesizing and cloning the resulting gene sequence, we achieve an expression vector that develops a cell line, which in turn produces a special recombinant antibody.

Better science with quality antibodies

Already in 2015, 100 of the world’s leading scientists collectively called for better standards and reproducibility in antibody production, proposing recombinant antibodies to circumvent variability (Baker, M. Reproducibility crisis: Blame it on the antibodies. Nature 521, 274–276 (2015). https://doi.org/10.1038/521274a). Moreover, by applying reverse engineering, which is encouraged by the EU Directive 2016/943 r, Miltenyi Biotec acts “[i]n the interest of innovation and fostering competition…” (§16).

Resources for CD45 Antibody, anti-non-human primate, REAfinity™
Certificates

To access a Certificate of Analysis (CoA) follow the link below and enter the specific lot of your product.

Get certificate

Should you wish to request additional documentation, such as a Safety Data Sheet (SDS) in other languages than English or Swedish, an SDS-replacement document, or a Certificate of Origin (CoO), please direct your inquiry to your local technical support team.

Contact technical support

You have previously chosen International as your location.
What do you want to do?